Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Tampon or cup? new study reveals hidden impact on Women's health

NCT ID NCT07199998

Knowledge-focused Sponsor: Centre National de la Recherche Scientifique, France Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study looks at how different menstrual products—tampons, cups, and pads—affect the bacteria and immune cells in the vagina. Researchers will collect samples from 300 women aged 18-49 to compare these groups. The goal is to understand if internal products like tampons and cups change vaginal health, which could help prevent infections and other issues.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

About 300 people

The number the study aims to enrol. It can still change while the study runs.

Started

Apr 2026

Expected to finish

Mar 2027

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

The study population includes individuals of the female sex, aged 18 to 49 years, who have already experienced at least one menstrual period and meet the inclusion criteria. Participants are residents of the Île-de-France region and are recruited either through the Alfred Fournier Institute or via an online epidemiological survey.

Ages

18 to 49 years

Sex

Female participants only

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Willingness to comply with all study procedures and availability for the duration of the study. * Female, aged 18 to 49 years. * In general good health, as determined by medical history. * Covered by the national health insurance system. * Willing to sign a written informed consent form. * Has already experienced menstruation prior to the start of the study. * No vaginal sexual intercourse within 72 hours before the study visit. * Has had at least 6 menstrual periods in the past 12 months. Exclusion Criteria: * HIV infection. * Positive diagnosis for chlamydia or syphilis at screening or within 4 weeks prior to screening. * History of hormonal disorders or menstrual cycle irregularities. * Metrorrhagia. * Pregnancy or breastfeeding. * Family members or close relatives of the clinical or scientific team. * Treatment with any medication for chronic inflammatory disease or chronic conditions (e.g., cancer, arthritis, transplantation) within the past 12 months. * Participation in an ongoing clinical trial. * Receiving or having received antibiotic treatment within the 4 weeks prior to the study. * Refusal to be informed in case of detected abnormalities. * Indistinct use of both tampons and menstrual cups. * Never having had vaginal penetrative intercourse.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Dysbiosis are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

bacterial vaginosis Dysbiosis fungal infectious disease human papilloma virus infection sexually transmitted disease toxic shock syndrome Urogenital Diseases

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Dysbiosis HPV Menstrual cup Mycosis Sexual transmitted disease Toxic shock syndrome Urogenital disease Vaginosis, bacterial

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Institut Alfred Fournier

    RECRUITING

    Paris, Île-de-France Region, 75014, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.